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Abstract: Primary liver cancer is the second leading cause of cancer-related death worldwide
and therefore a major public health challenge. We review hypotheses of the cell of
origin of liver tumorigenesis, and clarify the classes of liver cancer, based on molecular
features and how these affect patient prognosis. Primary liver cancer comprises
hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other
rare tumors, notably fibrolamellar carcinoma and hepatoblastoma. The molecular and
clinical features of HCC vs iCCA are distinct, although they have overlapping risk
factors and pathways of oncogenesis. A better understanding of the cell types
originating liver cancer can aid in exploring molecular mechanisms of carcinogenesis
and therapeutic options. Molecular studies have identified adult hepatocytes as the cell
of origin. These cells have been proposed to transform directly into HCC cells (via a
sequence of genetic alterations), to de-differentiate into hepatocyte precursor cells
(which then become HCC cells that express progenitor cell markers), or to trans-
differentiate into biliary-like cells (which give rise to iCCA). Alternatively, progenitor
cells also give rise to HCCs and iCCAs with markers of progenitor cells. Advances in
genome profiling and next-generation sequencing have led to the classification of
HCCs based on molecular features, and assigned them to categories such as
proliferation-progenitor, proliferation-transforming growth factor beta, and Wnt-catenin
beta 1. iCCAs have been assigned to categories of proliferation and inflammation.
Overall, proliferation subclasses are associated with a more aggressive phenotype and
poor outcome of patients, although more specific signatures have refined our
prognostic abilities. Analyses of genetic alterations have identified those that might be
targeted therapeutically, such as fusions in the FGFR2 gene and mutations in genes
encoding isocitrate dehydrogenases (in approximately 60% of iCCAs) or amplifications
at 11q13 and 6p21 (in approximately 30% of HCCs). Further studies of these
alterations are needed before these can be used as biomarkers in clinical decision
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ABSTRACT  
 
Primary liver cancer is the second leading cause of cancer-related death worldwide and 
therefore a major public health challenge. We review hypotheses of the cell of origin of liver 
tumorigenesis, and clarify the classes of liver cancer, based on molecular features and how 
these affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), 
intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma 
and hepatoblastoma. The molecular and clinical features of HCC vs iCCA are distinct, although 
they have overlapping risk factors and pathways of oncogenesis. A better understanding of the 
cell types originating liver cancer can aid in exploring molecular mechanisms of carcinogenesis 
and therapeutic options. Molecular studies have identified adult hepatocytes as the cell of origin. 
These cells have been proposed to transform directly into HCC cells (via a sequence of genetic 
alterations), to de-differentiate into hepatocyte precursor cells (which then become HCC cells 
that express progenitor cell markers), or to trans-differentiate into biliary-like cells (which give 
rise to iCCA). Alternatively, progenitor cells also give rise to HCCs and iCCAs with markers of 
progenitor cells. Advances in genome profiling and next-generation sequencing have led to the 
classification of HCCs based on molecular features, and assigned them to categories such as 
proliferation progenitor, proliferation transforming growth factor beta, and Wnt catenin beta 1. 
iCCAs have been assigned to categories of proliferation and inflammation. Overall, proliferation 
subclasses are associated with a more aggressive phenotype and poor outcome of patients, 
although more specific signatures have refined our prognostic abilities. Analyses of genetic 
alterations have identified those that might be targeted therapeutically, such as fusions in the 
FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 
60% of iCCAs) or amplifications at 11q13 and 6p21 (in approximately 30% of HCCs). Further 
studies of these alterations are needed before these can be used as biomarkers in clinical 
decision making.   
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Liver cancer is the second most common cause of cancer-related death worldwide and one of 
the few neoplasms whose incidence and mortality have been steadily increasing1, 2, with the 
highest increase in mortality in the United States (US) during the last 2 decades (Figure 13). 
Liver cancer comprises a heterogeneous group of malignant tumors with different histologic 
features and unfavorable prognosis that range from hepatocellular carcinoma (HCC) and 
intrahepatic cholangiocarcinoma (iCCA) to mixed hepatocellular-cholangiocarcinoma (HCC-
CCA), fibrolamellar HCC, and the pediatric neoplasm hepatoblastoma4, 5. Among these, HCC 
and iCCA are the most common primary liver cancers, whereas the other neoplasms, including 
mixed HCC-CCA tumors5, account for less than 1% of cases. The burden of liver cancer is 
increasing globally—there could be 1 million cases by 20306. It is not clear how direct-acting 
antiviral (DAA) agents, which can cure hepatitis C virus (HCV) infection, will affect the burden of 
HCC. It has been estimate that curing more than 90% of patients with HCV infection would 
eliminate 15% of HCC cases in the US7. However, there is debate over the effects of DAA 
agents on progression of HCC8-11. 
 
HCC alone accounts for 90% of all primary liver cancer cases with nearly 800,000 new annual 
cases2. Its highest incidence is in Asia and Sub-Saharan Africa due to the high prevalence of 
hepatitis B virus (HBV) infection6. Unlike other cancers, the main risk factors associated with 
HCC are well defined and include viral hepatitis (B and/or C), alcohol abuse and non-alcoholic 
fatty liver disease in patients with metabolic syndrome and diabetes. Other co-factors of HCC 
development, such as aflatoxin B1 and tobacco, increase the incidence of the disease if other 
common risk factors are present12. 
 
iCCA is the second most common liver cancer, with the highest incidence in Southeast Asia 
(30–40 cases/105 inhabitants) and low incidence in Western countries (fewer than 5 cases/105 
inhabitants)13. Nevertheless, steady increases have been reported13, 14. Risk factors for iCCA 
development include primary sclerosing cholangitis (PSC), biliary duct cysts, hepatolithiasis and 
parasitic biliary infestation with flukes—an etiology prevalent in Asia and linked to a specific 
molecular fingerprint13. More recently, shared risk factors with HCC have also been identified, 
such as HBV and HCV—particularly for iCCAs that develop in cirrhotic liver15.  
 
HCC and iCCA have been considered to be independent tumors that originate from distinct cell 
populations. However, more recently, some have been recognized as tumor subtypes of a 
continuum spectrum of diseases. We review the theories behind the cell(s) of origin of liver 
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cancer, describe emerging molecular classes, link these classes with their etiology and 
prognosis, and define pathways for future translation.  
 
CELL(S) OF ORIGIN 
Parenchymal (hepatocytes and cholangiocytes) and non-parenchymal cells (fibroblasts, stellate 
cells, Kupffer cells, and endothelial cells) form the basic hepatic structure (Figure 2); the 
existence of stem cells in adult liver has been heavily debated. Hepatocytes constitute 60%
80% of the total liver mass. Architecturally, these cells are organized in lobules, which can be 
further divided in functional regions or zones16. Liver zonation is particularly relevant for 
hepatocytes, since it affects their function without altering their phenotype. Hepatocytes are 
frequently polyploid (4N, 8N, etc.); polyploid cells make up 50% of human liver and 90% of 
mouse liver17.  
 
Liver tumors are heterogeneous in morphology, within the same and between different tumors. 
Some subtypes of HCCs and iCCAs have stem cell features18-20, such as HCCs with CK19-
positive cells21. The rare, mixed HCC-CCAs have cells with a phenotype that is intermediate 
between hepatocytes and cholangiocytes22. These observations have led to several hypotheses 
about liver . Hepatic progenitor cells might generate primary liver tumors 
because, during liver development, hepatocytes and cholangiocytes each arise from a common 
progenitor (hepatoblasts). Or, HCC and iCCA might be distinct tumors that originate from 
mature hepatocytes and cholangiocytes, respectively.  
 
We review findings from recent studies indicating that adult hepatocytes are the source of 
HCCs, because they can directly degenerate into HCC following sequential genomic insults, de-
differentiate into precursor cells that ultimately can transform into HCC cells with markers of 
progenitor cells, and trans-differentiate into biliary-like cells able to transform into iCCA23-25 
(Figure 3). In parallel, progenitor cells may also give rise to HCCs and iCCA with progenitor-like 
features, whereas adult cholangiocytes, which lack the plasticity and transforming capacity of 
hepatocytes, can only give rise to iCCAs26.  
 
Progenitor cells and hepatocytes in liver regeneration 
Adult stem cells or somatic stem cells are defined as undifferentiated cells with limitless 
replicative potential. They can differentiate into all or some specialized cell types, and their 
primary role is to sustain physiological tissue turnover and to direct tissue repair upon different 
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types of injury27. Stem cell compartments have been successfully identified in several adult 
tissues with fast turnover, including the gastrointestinal tract, skin, and bone marrow. Because 
of their self-renewal potential and long lifespan, these cells are thought to be more prone to 
malignant transformation28, 29 and have been identified as the cell of origin of cancer in several 
organs, for example skin and intestine30-32. Unlike these organs, however, cells of the adult liver 
have relatively slow turnover (a period of several months), with an average hepatocyte life span 
ranging from 200 to 300 days33, 34. In this context, the contribution of stem cells to liver turnover 
is unclear (reviewed in ref. 35).  
 
Hepatocytes are quiescent in normal liver, but their turnover in the liver dramatically accelerates 
upon hepatic injury or after a significant reduction of liver mass such as following partial 
hepatectomy. Under these conditions, adult hepatocytes have enormous proliferative potential 
(capacity to replicate more than 50 times), a feature that has enabled human liver organ donor 
transplantation as a standard procedure to treat end-state liver disease33-35. There is evidence 
that regeneration after partial hepatectomy relies predominantly on the replication of 
hepatocytes, rather than stem cells. However, when the replicative capacity of hepatocytes is 
severely impaired, such as in patients with acute liver failure or chronic hepatitis, epithelial cells 
with intermediate hepatocyte cholangiocyte phenotypes emerge and expand36-38. These cells, 
also known as oval cells, are thought to localize to the peri-portal area in the canals of Hering 
and are considered to be bi-potential progenitors35, 39 (Figure 2). The capacity of these cells to 
repopulate the damaged liver has been demonstrated in mice with massive liver damage, 
restoring more than 80% of hepatocytes40. Other studies from liver injury models have 
supported the liver stem cell hypothesis, showing proliferation of duct-like cells, frequently 
termed the ductular reaction, in the portal zone of the hepatic lobule41-43. However, this feature is 
controversial44, 45.  
 
Other cells have been implicated in regeneration, repair, and eventually carcinogenesis. HCV-
related chronic injury can induce ductular metaplasia and proliferation, with mature hepatocytes 
trans-differentiating to bi-potential oval cells via epigenetic re-programing25. These cells are 
different from the classical oval cells of the canals of Hering, and may have a more relevant role 
in hepatocarcinogenesis. However, other sources of precursors have been identified. These 
include specialized peri-central liver cells, capable of self-renewal in the uninjured liver under 
the influence of endothelial Wnt signaling46. These pericentral cells express the early liver 
progenitor marker TBX347 and are diploid. Hybrid periportal cells express hepatocyte markers, 
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along with low levels of SOX9 and several bile duct genes, are able to repopulate the healthy 
and diseased liver mass48. It is not clear whether these cell populations are bona fide stem or 
progenitor cells, or distinct hepatocyte subpopulations, and whether they contribute to 
tumorigenesis49.  
 
Progenitor cells as precursors  
Extensive experimental studies support the hypothesis that progenitor cells might originate liver 
cancer50-52 (Table 1). For example, mice with genetic alterations that affect the Hippo pathway 
within the liver expand progenitor-like cells and subsequently develop HCC, iCCA, and mixed 
HCC-CCA53-55. Similarly, liver-specific deletion of the neurofibromatosis type 2 (NF2) tumor 
suppressor gene in developing or adult mice leads to expansion of progenitor cells without 
affecting differentiated hepatocytes; these mice develop HCC and iCCA56. Furthermore, any 
mouse hepatic cell, including hepatic progenitors, hepatoblasts, and hepatocytes, that express 
activated oncogenes (such as H-RAS or SV40LT) can undergo transformation to develop into 
iCCAs or HCCs57 (Table 1). There could also be subpopulations of stem or progenitor cells in 
peribiliary glands, located throughout the biliary tree,58 that give rise to iCCAs59 or fibrolamellar 
HCC60. Proteins involved in stem cell renewal and cell fate decisions include MET50, which 
primarily induces hepatocyte differentiation, and EGFR and Notch, which promote cholangiocyte 
specification50, 51. Activation of Notch in mice leads to development of HCC61 and iCCA62. In 
addition, mutations in genes encoding isocitrate dehydrogenases, frequently detected in 
iCCAs14 but rarely in HCCs, inhibit hepatocyte differentiation and promote oval cell proliferation 
and biliary transformation following liver injury, in cooperation with KRAS mutations63 (Table 1). 
Similarly, KRAS mutations and homozygous PTEN deletion in embryonic bi-potential progenitor 
cells cooperate to induce onset of iCCA64. Overall, these experimental studies implicate 
progenitor cells in the development of the two most common primary liver cancers.  
 
Adult hepatocytes as cell of origin 
There is significant experimental evidence implicating adult hepatocytes as the cell of origin in 
liver cancer48, 65-69. Studies using fate-tracing systems have observed that HCC does not 
originate from progenitor cells, but rather from hepatocytes in both hepatotoxin-induced66, 67 and 
carcinogen-free (Mdr2 knock-out) models65, 67 (Table 1). In particular, these data indicate that 
Foxl1+ cells, which express the progenitor markers EPCAM, SOX9, PROM1, do not contribute 
to HCC tumorigenesis66, in agreement with other studies showing that biliary cells do not give 
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 rise to HCC65. In addition, a recent study has demonstrated that hepatocyte-specific p62 
expression promotes c-MYC induction, mTORC1 activation and HCC initiation70.  
Adult hepatocytes, however, have additional properties consistent with a cell that originates 
cancer. These include their remarkable plasticity, which entails their capacity to de-differentiate 
into a progenitor state and then can restore the hepatocyte pool25. Mature hepatocytes can de-
differentiate following loss of the tumor suppressor TP53, which yields nestin-positive 
progenitor-like cells that can expand and generate primary liver cancers after acquiring lineage-
specific oncogenic lesions, such as mutations in WNT (in HCC) or Notch (in iCCA)52 (Table 1). 
In addition, adult hepatocytes can also trans-differentiate into biliary-like cells (Figure 3)24 that 
can degenerate into iCCA. Upon injury, Notch activation leads to reprogramming of mature 
hepatocytes into cells that closely resemble biliary epithelial cells,71 to induce iCCA. Notch can 
do this on its own72 or in cooperation with AKT73 (Table 1).  
There is evidence that different cell types can serve as the cell of origin for primary liver cancers 
(Figure 3, Table 1). Two complementary features of HCC and ICCAs could account for their 
phenotypic complexity, their molecular features (pathways of activation, mutations, etc.), and 
the types of cells that become transformed. For example, development of HCC could involve 
specific molecular alterations in adult hepatocytes (Figure 3), whereas iCCA could originate 
from cholangiocytes, probably as a result of chronic biliary damage due to liver flukes, PSC, or 
other insults.  
 
However, adult hepatocytes have also been implicated in the formation of other tumor types. 
First, tumors with progenitor cell phenotype could derive from progenitor-like cells, either 
because they are bona fide progenitor cells or following de-differentiation of adult hepatocytes. 
Transformation of progenitor cells could occur at any stage of hepatic development from 
progenitor to adult liver cells giving rise to tumors of different morphologies, ranging from HCC 
and iCCA with stem-cell phenotypes to mixed HCC-CCAs (Figure 3). Clinical and pathology 
analyses of mixed HCC-CCAs have indicated an origin from the progenitor cell compartment5, 14, 
74. Finally, mature hepatocytes can trans-differentiate, generally as a results of viral infection, to 
biliary-like cells that give rise to iCCA.  
 
Regardless of their cell of origin (mature hepatocytes vs progenitor cells), liver cancers with 
stem cell features have a more aggressive clinical behavior and worse prognosis than those 
without stem cell features 19, 21. However, these are difficult to study due to discrepancies 
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between mice and humans. Studies are needed to determine under what circumstances adult 
hepatic cells, rather than progenitor cells, give rise to liver tumors and vice versa, and to fill the 
gap between findings from animal models (cell fate tracing studies) and studies patients with  
severe liver injury. It will also be important to determine the dominant reprogramming events 
involved in tumorigenesis in different species. Studies should explore which cells are most 
affected by oncogene mutations associated with HCC, such as those in the TERT promoter or 
CTNNB1. 
 
Immune Response 
Regardless of the cell type that becomes transformed to initiate tumorigenesis, the developing 
tumor also requires a specific microenvironment. This is particularly relevant to liver tumors, 
90% of which develop under conditions of chronic inflammation2. Factors that contribute to 
tumor formation include changes in the extracellular matrix, signaling between 
parenchymal and non-parenchymal cells, and immune dysfunction75. An altered immune 
response is an important factor in carcinogenesis.76 Cancer cells produce growth and 
angiogenic factors that promote tumor growth, invasion, and metastasis. iCCAs develop under 
conditions of chronic inflammation, due to viral infections (in about 20% of cases), chronic fluke 
infestation, PSC, and hepatolithiasis13.  
 
Chronic inflammation contributes to liver carcinogenesis through a cycle of cell death and 
regeneration, leading to production of cell survival and proliferation signals that promote 
formation of regenerative nodules, dysplasia, and cancer75. In this context, the phenotype of 
liver tumors could depend on interactions between oncogenes and the immune 
microenvironment. In a recent animal study, different types of liver tumors, such as HCCs, 
iCCAs, and mixed HCC-iCCA arise via activation of distinct oncogenes, such as AKT1 and 
CTNNB1, in combination with inflammatory microenvironment conditions, such as carbon 
tetrachloride or 3,5-diethoxycarbonyl-1,4-dihydrocollidine77. Tumors that develop via activation 
of the same oncogenes can still have different transcriptomes, depending on level of 
inflammation and features of the microenvironment.  
  
Several mechanisms have linked the immune system with liver cancer development. First, 
secretion of cytokines by immune cells, such as tumor necrosis factor and IL6, can activate 
inflammatory signaling pathways in hepatocytes, via JAK STAT, nuclear factor (NF)-kB, etc., to 
promote cell proliferation and survival 75. A model of HCC tumorigenesis has been proposed in 
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which leukocytes that infiltrate the liver organize into ectopic lymphoid-like structures, providing 
microniches that contain malignant hepatocytic progenitor cells78. The role of the adaptive 
immune system is becoming apparent from studies of animal models of liver cancer 
development with non-alcoholic steatohepatitis. Factors that activate inflammation, such NF- B 
and insulin receptor, contribute to carcinogenesis in patients with non-alcoholic fatty liver 
disease79. CD8+ and CD4+ T cells and natural killer cells 80,81 also promote oncogenesis.  
 
The interaction between inflammation and iCCA development has been demonstrated in mice in 
which biliary epithelial cells that express transgenic AKT and YAP develop only iCCA upon 
promotion of IL33-mediated biliary tract inflammation82. Other inflammatory mediators that 
contribute to oncogenesis include IL6 and iNOS83. IL6 is highly expressed in human CCAs and 
promotes cell survival in a STAT3-dependent manner84. Interestingly, a gene expression 
signature associated with IL6 STAT3 signaling has been observed in a subset of human 
iCCAs85. 
 
Normally, nascent transformed cells are eliminated by both the innate and adaptive immune 
systems in a process called immune surveillance. Cancer cells express antigens that induce 
adaptive responses mediated by T cells86. In the chronically inflamed liver, immune surveillance 
prevents proliferation and expansion of cancer cells. Some, but not all, recent reports have 
warned about an unexpectedly higher incidence of HCC occurrence and recurrence in patients 
treated with DAAs for HCV infection8-11. If confirmed, the potential role of immune system should 
be explored, because rapid clearance of HCV in patients with chronic infection for years might 
affect immune surveillance.  
 
Immune therapies 
The immune microenvironment of HCC is characterized by the co-existence of immune 
responses leading to both immunogenicity and tolerance87. HCCs promote immunotolerance 
through the release of cytokines such as interleukin 10 (IL10) and transforming growth factor 
beta (TGFB). The tumors and tumor-infiltrating immune cells also express immune regulators 
such as programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T-lymphocyte 
protein 4 (CTLA4), which suppress the anti-tumor immune response, allowing tumor growth and 
progression87, 88. Tumors with immune infiltrates have been associated with longer survival 
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times and reduced relapse after resection and transplantation2, 88. In addition, some HCC cases 
of spontaneous regression have been linked to immune-mediated mechanisms2. These 
observations establish the rationale for immunotherapy of HCC. Promising responses have 
been reported with nivolumab, a monoclonal antibody directed against PD1, in a phase 2 trial89. 
It appears that a T-cell response, features of inflammatory cells (PD1, PDL1 expression), 
number of mutations in tumor cells, and gene expression profiles might predict patient 
responses90-93. Using source separation techniques to dissect gene expression patterns of 
tumor cells from those of tumor-infiltrating immune cells, an immune-specific subclass has been 
identified in 25% of HCC patients94. This subgroup is characterized by activation of immune 
cells, expression of PD1 and PDL1, and enrichment in signatures of response to 
immunotherapies. Furthermore, 2 robust microenvironment-based types have been identified, 
with either active or exhausted immune responses; these findings could be used to improve 
design of clinical trials of immunotherapies94. Similarly, a subtype of iCCA characterized by high 
mutation load and increased expression of immune checkpoint genes has been identified that 
may predict response to immunotherapies95.  
 
Classification Based on Molecular Features 
Characterization of molecular subtypes and/or oncogene-addiction loops has generated 
treatment algorithms for several types of cancer, including breast cancer; these have improved 
patient outcomes. High-throughput technologies, including single-nucleotide polymorphism 
arrays, combined with transcriptomic and exome sequencing analyses, have identified 
molecular subtypes of liver cancer, with distinct oncogene signaling pathways and recurrent 
mutations96. Even though molecular classifications have not affected decision making for 
patients with liver cancer, correlations between these subclasses and clinical and pathology 
characteristics (such as risk factors, outcome, etc.) have been proposed.  
 
Reaching a consensus 
The development of a molecular classification of HCC has paralleled the progress in genomic 
profiling technologies, and is extensively reviewed elsewhere97. Initial studies relied on 
differences in gene expression patterns determined by microarrays, whereas more recent, 
sequencing-based studies used mutation signatures to classify HCCs3. Unsupervised clustering 
of gene expression patterns accurately identified 2 major subgroups (reviewed in2, 97). These 2 
classes, broadly termed proliferation and non-proliferation, correlate with clinical and pathology 
features, etiology, and patient outcomes97. Tumors of the proliferation class are highly 
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heterogeneous with significant enrichment in signaling pathways related to proliferation, such as 
insulin like growth factor 1 (IGF1)98 and mechanistic target of rapamycin (MTOR) or stem cell 
features, such as Notch61. This class also contains most gene expression patterns associated 
with tumor recurrence99 and shorter survival time100 (Figure 4). Epigenetic features, such as 
expression patterns of micro RNAs 101 and DNA methylation patterns,102 also associate with 
these subclasses. Chromosomal aberrations are also frequent in HCCs—mostly in 
chromosomes 1 and 8—which correlate with transcriptome-based subclasses. High-level 
amplifications have been reported at Chr. 11q13 (at CCND1 and FGF19) and 6p21 (at VEGFA); 
gains in 11q13 are enriched in tumors from the proliferation subclass (Figure 4). Tumors in the 
non-proliferation subclass tend to retain hepatocyte-like features; a subset has activation of the 
canonical WNT signaling pathway, mostly via mutations in CTNNB197. This class contains many 
less-aggressive, well-differentiated tumors with low levels of alpha fetoprotein, compared to the 
proliferation class. In parallel, molecular analyses of the adjacent non-tumor tissues have 
provided valuable insights into mechanisms that promote hepatocarcinogenesis, including 
aberrant EGF signaling and activation of inflammation pathways (involving NF-kB and IL6)103, 
104. 
 
Next-generation sequencing (NGS) has provided a more detailed picture of molecular 
alterations in HCCs105. This technique can be used to define mutation signatures—recurrent 
patterns of nucleotide substitutions across different samples. These data provide for an 
additional layer of stratification beyond transcriptome-based classes. Interestingly, mutation 
signatures can reflect the exposure history of a tumor. In HCC, specific mutation signatures are 
associated with environmental exposures such as smoking, alcohol, aflatoxin B1 or aristolochic 
acid96 (Figure 4). Data from exome sequencing of large patient cohorts have confirmed the 
most prevalent mutations in HCC pathogenesis106, 107 (such as the TERT promoter, CTNNB1, 
TP53, AXIN1, ARID1A), but also uncovered novel low-frequency events106, 107 and implicated 
mutations in non-coding DNAs108. In addition, NGS has also provided a map of viral integrations 
in HCC, mostly related to HBV109 and more recently for the adeno-associated virus type 2 
(AAV2)110. Recurrent clonal HBV integrations affect TERT, MLL4 and CCNE1, some of which 
may impact patient survival109. AAV2-mediated insertional mutagenesis has been reported in 
5% of HCC, mostly in non-cirrhotic patients without a clear etiological factor, predominantly 
affecting TERT, KMTB2, CCNA2 and CCNE1110.  
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Obstacles to clinical implementation 
Ultimately, molecular classification of both the tumor and its microenvironment will translate into 
more effective clinical decision-making and treatment selection. This means optimizing clinical 
staging systems, both in their ability to predict prognosis and in their capacity to stratify patients 
based on response to therapies. Despite substantial progress, clinicians cannot yet use 
molecular information to guide therapy, primarily because there are not yet biomarkers that 
predict the response to a given therapy, unlike other malignancies. For instance, lung cancer 
patients with ALK rearrangements have a significantly better response to ALK inhibition with 
crizotinib than those without ALK rearrangements111.  
 
There are several reasons that molecular information on tumors is not incorporated into clinical 
practice. Unlike other solid tumors, the most frequent mutations in HCC are un-targetable, 
including those in the TERT promoter (60%–70%), TP53 (25%–50%) and CTNNB1 (25%–30%). 
Furthermore, the few potentially actionable events uncovered have not yet been evaluated in 
clinical trials that include biomarkers. Only recently have some potential biomarkers been tested 
in early clinical trials, such as FGFR4 inhibitors in patients with high level amplifications of 
Chr11q13, locus of FGF19112. Finally, a therapeutic response to blocking an oncogene in a few 
patients will be lost among many patients who lack a responsive phenotype if the trial has not 
been enriched to include those patients whose tumors harbor targetable defects. A recent report 
suggests that TSC2 loss predicts response to the MTOR inhibitor everolimus in different 
experimental models of HCC113, yet there is no clear biomarker of treatment response in the 
phase 3 clinical trial114. Indeed, the two systemic therapies that increase survival in HCC 
patients in first (i.e., sorafenib115) and second line (i.e., regorafenib116) have been tested in ‘all-
comers’, with no patient enrichment strategy. 
 
Options to improve the current trial strategy could include conducting clinical trials with enriched 
populations, based on biomarkers that predict response (FGF19117, MET). Or they could 
investigate non-mutated de-regulated pathways as targets, such as IGF298, or NOTCH61 
signaling. It might also be possible to use alternative anti-tumor approaches, such as immune 
checkpoint inhibitors, or strategies to antagonize the most prevalent genetic defects found in 
HCCs, such as mutations in TERT, TP53 and CTNNB1. 
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Molecular Subclasses of iCCA  
There is no effective treatment for iCCA. Reasons include our poor understanding of its 
pathogenesis and the lack of studies conducted specifically in patients with iCCA, apart from 
patients with all biliary tract cancers13, 14; this is important because iCCAs are characterized by a 
distinct set of mutations14. iCCAs were only recently recognized as a distinct entity with both its 
own unique staging system (see the 7th edition of the American Joint Committee on Cancer 
Staging Manual118) and ad hoc practice guidelines [see guidelines of the International Liver 
Cancer Association (ILCA)13]. The classification of iCCA’s distinct phenotype has led to the first 
studies that characterize its genomic landscape in order to generate an initial molecular 
classification. Other CCA, such as perihiliar (pCCA) and distal (dCCA) are different molecular 
entities14. 
 
Two main molecular subtypes of iCCA, proliferation and inflammation, have been proposed 
based on an integrative analysis of whole-genome expression patterns, chromosomal 
aberrations, mutation, and alterations in signaling pathways in a large cohort from USA and 
Europe85. The inflammation subclass was characterized by activation of inflammatory pathways, 
overexpression of cytokines, and STAT3 activation, whereas the proliferation subclass was 
characterized based on activation of oncogene signaling pathways (KRAS, EGFR, and Notch) 
and HCC gene expression signatures associated with short survival times and earlier 
recurrence85. While neither of the two subclasses displayed specific broad chromosomal gains 
and losses, the proliferation subclass is enriched in focal aberrations including DNA 
amplifications at 11q13.2 (locus of CCND1 and FGF19), and deletions at 14q22 (locus of 
SAV1). The proliferation class also includes a subtype with stem cell–like features119, 
chromosomal instability85 and mutations in isocitrate dehydrogenase genes63 (Figure 5). Clinical 
characteristics such as moderate/poor differentiation, intra-neural invasion and poor outcome 
are significantly more frequent in the proliferation class. Interestingly, there is a genomic 
resemblance observed between the proliferation subclass of iCCA and HCC subtypes with poor 
prognosis (i.e. cluster A19, G3120) and stem cell features (S2)121, 122 (Figure 5). This evidence 
further supports the presence of a common cell of origin in liver cancers. 
 
An independent whole-transcriptomic analysis of a large cohort including iCCA and extrahepatic 
cholangiocarcinomas also confirmed the existence of the two prognostic CCA molecular 
subtypes123. In this study, two main classes were reported: a poor prognosis group 
characterized by enrichment of RAS mutations, MET and EGFR overexpression, and a good 
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prognosis subgroup characterized by signatures of immune response123. Genomic overlap 
between the poor prognosis group123 and the proliferation subclass was observed85. 
Similar to HCC, NGS studies have generated insights into the molecular subtypes of iCCA95, 124-
131. The most common genetic aberrations include FGFR2 gene fusions (~25%) and mutations 
in KRAS (20%), IDH1/2 (~20%) and chromatin remodeling genes [ARID1A, BAP1, PBRM1, 
~30%,] (reviewed elsewhere 14). Besides IDH1 and IDH263, KRAS,85, 123 and EGFR85 mutations, 
which are enriched in the proliferation subclass, no significant distribution of other molecular 
aberrations has been reported in any of the iCCA molecular subtypes.  
The incidence of iCCA varies significantly among geographic regions. Incidence is highest in 
Asian countries, where infections with liver flukes such as Opisthorchis viverrini and Clonorchis 
sinensis are the major risk factor13. In non-endemic regions, other factors, including 
hepatolithiasis and PSC, likely contribute to risk. Associations between different risk factors and 
mutations detected in iCCAs were explored in 209 CCAs from Asia and Europe. Mutations in 
BAP1 and IDH1/2 were found in a higher proportion of non-O viverrini-related iCCAs (22% vs 
3.2%), whereas mutations in TP53 were found in a higher proportion of tumors from patients 
with O viverrini infection (45.2% vs 7.4%)124. Although there have been other studies of large 
cohorts of patients, it has been difficult to draw conclusions from these due to the different types 
of neoplasms included (iCCAs, extrahepatic cholangiocarcinomas, and gallbladder tumors)85, 123. 
 
Importantly, multiple FGFR2 gene fusions have been discovered in approximately 25% of 
iCCAs126, 127, 132-135 (reviewed in ref. 14); these are used to define tumor subtypes. Tumors with 
FGFR2 fusions and KRAS mutations126 or BAP1 mutations95 have been reported. No significant 
differences in patient age or outcome, or tumor differentiation or stage, were found in comparing 
patients with or without the FGFR2 fusion. One study reported a higher frequency of HCV 
infection in patients with FGFR2 fusions132, although this finding has not been confirmed95, 126, 
134. Early-phase clinical trials testing selective FGFR inhibitors in advanced iCCA patients 
carrying alterations in FGFR2 are underway (NCT02150967 and NCT01752920) 136, 137. These 
studies reported an objective response rate of approximately 15% (a signal of efficacy) and 
manageable safety profile136. The discovery that FGFR2 fusions can promote development of 
iCCAs has been quickly translated to clinical trials. Fusions of the FGFR2 gene might be used 
as biomarker to select patients for treatment with these agents.  
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Molecular Features of Uncommon Tumors 
Fibrolamellar HCC (FLC) is a rare primary liver cancer with few treatment options that typically 
affects children and young adults without background liver disease60. FLC is now considered a 
unique molecular entity within primary liver malignancies138. FLC is caused by an approximate 
400 kb deletion in chromosome 19 that incorporates the first exon of DNAJB1 into all but the 
first exon of PRKACA139. This fusion is detected in 70%138 to 100% of FLCs139. In addition, 
exome sequencing and RNA sequencing studies found de-regulation of additional actionable 
candidates such as ERBB2 and AURKA140. Unlike HCC or iCCA, there are no prevalent 
mutations in more than 10% of patients. Unsupervised clustering of gene expression data 
identified FLC molecular subclasses in a cohort of 58 FLCs, 2 of them associated with 
proliferative and inflammatory molecular traits. The same study provided a prognostic 8-gene 
expression signature138. FLC has less chromosomal aberrations compared to HCC or iCCA 
without recurrent high-level amplifications or deletions.  
 
Hepatoblastoma is the most frequent primary liver tumor in children younger than 5 years old. 
Like FLC, background liver disease is rare in these patients. WNT signaling plays a major role, 
with CTNNB1 mutations (70%) as the most frequently reported molecular event. Integrative 
analysis of gene expression and chromosomal aberrations in 24 hepatoblastoma samples 
distinguished 2 classes, with different DNA gains, histological phenotype and clinical 
outcome141. The recent use of patients-derived xenografts (PDX) in hepatoblastoma enabled the 
identification of novel therapeutic targets such as NRAS mutations142, 143.  
 
Mixed HCC-iCCA is a rare neoplasm accounting for less than 1% of all primary liver cancers5. 
Diagnosis is mainly based on histological examination and requires features of HCC and iCCA. 
According to the 2010 World Health Organization classification, there is a classical type, 
characterized by areas of typical HCC and iCCA with a transition area, and a stem cell-feature 
type144. The stem cell-feature type can be further divided into typical, intermediate, and 
cholangiolocellular carcinoma (CLC) subtypes. Gene expression profiling of small series of 
HCC-CCA samples indicated that this tumor type might share common characteristics with 
poorly differentiated HCC and iCCA with stem cell traits119, 122, 145. A comprehensive integrative 
genomic analysis of 18 mixed HCC-CCA subtypes defined 3 molecular types (CLC, stem cell, 
and classical subtype)146. In particular, the CLC subtype, despite being grouped, based on 
histology, within the stem cell-feature subtype, has a unique molecular profile, with biliary traits, 
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low levels of chromosome instability, and activation of TGFB and inflammation-related signaling 
pathtways146. 
 
Challenges in tumor heterogeneity  
Liver tumors have a high degree of molecular heterogeneity, not only among patients with the 
same types of tumors, but also within regions within the same tumor or tissue147. Expert 
recommendations and consensus definitions have been established to better address the extent 
and role of cancer heterogeneity in oncology research148.  
 
From a clinical perspective, molecular heterogeneity should be considered within the concepts 
of trunk and branch, and driver and passenger mutations. Trunk mutations (mutations that occur 
early in tumorigenesis) can be found in every cancer cell of a tumor 148. Branch mutations are 
found in only a subgroup of tumor cells; these are acquired at later stages of tumor 
development, frequently following treatment, and are associated with resistance. Studies of 
other malignancies have indicated that trunk mutations promote tumor progression, and are 
therefore the best targets for therapies. Trunk mutations identified in single-biopsy should be the 
first targets of molecular therapies 2. Finally, passenger mutations account for the most common 
type of mutations, but their relevance to tumor development is marginal. However, they are 
often used to define a tumors’ clonal features and anti-tumor response. 
 
Prognostic Markers 
Molecular biomarkers have many applications in cancer. The can improve clinical decision 
making by helping to predict a patient’s outcome, select the patients most likely to respond to a 
specific treatment, and avoid treatments not likely to be effective. Unlike other cancers such as 
breast149 and colorectal150 cancers, HCC has no molecular markers that have been incorporated 
into clinical management.  
 
As a general rule, clinical practice guidelines include recommendations based on a specified set 
of metrics, which rate the level of evidence and the strength of recommendations for each 
statement; the higher the evidence, the stronger the recommendation. For example, sorafenib is 
recommended for treatment of patients with advanced-stage HCC; a strong recommendation 
was derived from a prospective, double-blind, randomized, placebo-controlled trial (the highest 
level of evidence)151. These metrics are less clear when evaluating biomarkers for HCC. Initial 
recommendations for biomarkers were developed mostly to address technical aspects of the 
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assay such as the Tumor Marker Utility Grading System152. This was later improved upon by the 
REMARK guidelines for reporting prognostic biomarker in oncology153, which also has 
addressed issues related to clinical utility. The PROGRESS initiative was the most recent 
attempt to provide a methodological framework for biomarker research154.  
 
The highest level of evidence in biomarker research (Level A) comes from randomized trials155. 
A large prospective study of 10,253 women demonstrated that a 21-gene expression signature 
could identify patients with early-stage breast cancer at high risk for recurrence156. Level B 
evidence is provided by companion studies of biomarkers in randomized clinical trials, such as 
those reported for HCC in the Sorafenib HCC assessment randomized protocol157 and 
everolimus for liver cancer evaluation114 trials. Neither of these studies identified markers 
associated with response to either sorafenib or everolimus, but they confirmed the prognostic 
role of levels of angiopoietin 2 and vascular endothelial growth factor in plasma of patients with 
advanced-stage HCC157. Level C evidence has been provided most frequently for markers of 
HCC, from studies of archived samples, with extensive validation (reviewed elsewhere)97. Most 
level C studies have evaluated prognostic markers, identifying patients with the proliferation 
subclass of tumor, either S1 (WNT and TGFB expression), or the S2 (progenitor cell) subtype-
97, with or without amplification of FGF19 106. The S2 subtype expresses many makers of 
progenitor cell cells and high levels of alpha fetoprotein. Tumors in the S1–S2 subgroups are 
poorly differentiated and patients have worse outcomes than patients with other HCC 
subtypes97. Level D evidence comes from studies of convenience, in which specimens were 
collected for unknown reasons and happen to be available for assay. 
 
Gene signatures associated with risk of HCC development may have a more direct application 
(Table 2)100, 102, 158-161. For instance, a 186-gene signature in liver tissues was able to predict 
occurrence of HCC158 in patients with hepatitis C-related early-stage cirrhosis, and might be 
used to select patients for trials of chemopreventive agents (Figure 4, Table 2). However, 
chemoprevention studies are a challenge, because it takes a long time to collect data on a low 
number of events. Studies that included populations of patients at high-risk for HCC may 
shorten trial time and identify effective agents more quickly. For predictive biomarkers in 
advanced HCC, ongoing clinical trials include populations selected based on high expression of 
MET in tumor cells (trial of tivantinib, NCT01755767) or high serum level of alpha fetoprotein 
(trial of ramucirumab, NCT02435433), both as second-line therapies. 
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Molecular markers of iCCA 
Even fewer biomarkers of iCCA have been developed than for HCC; there is only level C data 
for the efficacy of a biomarker for this tumor type. iCCA is one of the few solid tumors for which 
no systemic molecular therapy has been approved by the Food and Drug Administration13. 
Surgery is the only potentially curative option, although chemotherapy with gemcitabine plus 
cisplatin is the standard for patients with advanced-stage iCCA162. According to the ILCA 
practice guidelines, no studies have provided level A or B evidence for a marker of this tumor—
some data from low-quality studies have led to weak recommendations13. These studies have 
been retrospective in design, without extensive validation in independent cohorts. Some gene 
expression and microRNA patterns have been associated with features of iCCA85, 119, 123, as well 
as mutations in KRAS and IDH1 or IDH2 and focal deletions at 14q22.185, 128, 129 (Table 2). Gene 
expression patterns have been reported to identify an iCCA proliferation subclass of tumor85, 
patients with a poor prognosis, 85, 123 and tumors with a stem cell–like subtype119, who have 
aggressive disease and worse outcome.  
 
Features of cancer cells in a tumor determine not only the tumor’s growth and progression, but 
also affect the tumor microenvironment (non-cancer cells and supporting stroma)76. Some 
studies associated features of the iCCA microenvironment with patient outcome123, 163-165. Two 
studies identified a stromal signature associated with shorter survival time by combining laser 
capture microdissection with gene expression profile analysis123, 165. Although many studies 
have validated gene expression signatures associated with patient outcomes, the clinical 
significance of microRNA signatures is not yet clear, due to the limited number of large 
comprehensive profiling studies119, 166-168.  
 
Mutations in oncogenes such as KRAS and BRAF can be used to determine prognosis for 
patients with pancreatic or colorectal cancers169-171. However, there is controversy over whether 
these mutations can predict outcomes of patients with iCCA. Some studies have reported 
significant associations between mutations in KRAS128, 129, 131 or chromatin-remodeling genes 
(BAP1, PBMR1, and ARID1A)125, 172 and either shorter disease-free survival or shorter overall 
survival, respectively. It is not clear whether mutations in IDH1 or IDH2 associate with overall 
survival 125, 129, 173.  
 
Most biomarker assays use cells or tissue collected by invasive biopsy procedures or from 
resection specimens, but these specimens are rarely collected from unresectable or metastatic 
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iCCAs—the tumors of most patients in clinical trials for iCCA. Strategies should be developed to 
assess circulating markers (called a liquid biopsy), from tumor cells and cell-free nucleic acids in 
blood174. Detection of molecular signatures or aberrations in the blood could significantly 
facilitate implementation of prognostic markers. Liquid biopsies might also be used to monitor 
response to treatment, especially in clinical trials of selective inhibitors of IDH1 and IDH2 
(NCT02073994, NCT02273739) and FGFR2 (NCT02150967)14, 136.  
 
Future Directions 
In the last decade, there have been tremendous advances in our understanding of the cellular 
and molecular complexity of liver cancers. Sophisticated functional studies and NGS-based 
research studies have provided information about the cells that form liver tumors and the 
proteins and pathways involved in hepatocarcinogenesis. These studies support a model of 
multiple cells of tumor origin. Most of the studies, using in vivo lineage tracing models, revealed 
an unexpected plasticity of mature hepatocytes24, 25, 44, 52, 72 that could be involved in their 
transformation into cancer cells. Hepatic progenitor cells might also become transformed to give 
rise to different subtypes of HCC, iCCA, and mixed HCC-iCCA with progenitor markers.  
 
Studies of humanized mice to mimic the onset of liver cancers in multiple settings may help 
address existing challenges. In addition, cell- and lineage-tracing models should improve so that 
they recapitulate the severity of liver injury observed in humans, and must clarify if hepatic 
progenitor cells can replenish the liver mass after marked liver injury, as demonstrated in 
zebrafish models175. Finally, linking the main genomic hits at pre-neoplastic and early stages of 
human cancer development with the cell of origin is also an area where further studies are 
required.  
 
Identifying the cells that give rise to liver tumors and elucidating the different classes of tumors, 
based on their molecular features, could lead to new approaches to treatment and prognosis. 
Our knowledge of the molecular mechanisms of HCC and iCCA pathogenesis has not yet been 
translated into clinical tools, because few studies have linked specific molecular classes of 
tumors or aberrations to responses to therapy. It is important to incorporate biomarker studies 
into trials, as in the trials of patients with iCCAs with FGFR2 aberrations136. The successes of 
immune therapies in different solid tumors, including HCC,176 indicate the need to focus greater 
attention on the hepatic tumor microenvironment and interactions between the tumor and the 
immune response; we also need to identify markers of response to these therapies. Learning 
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more about the effects of tumor heterogeneity, and the use of liquid biopsies to determine the 
molecular and genetic features of patients’ tumors, could overcome barriers to personalized 
treatment of liver cancer174.  
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FIGURE LEGENDS 
 
Figure 1: Mortality trends of patients with different malignancies in the USA from 
1990through 2009 (reprinted from ref 3). Changes in cancer mortality, among tumor types, in 
the US. Mortality from liver and bile duct cancers is increasing more rapidly than any other 
cancer, in men and women. Data obtained from the 2013 American Association for Cancer 
Research Cancer Progress Report. 
 
Figure 2: Structure of the liver lobule and location of candidate cell of origin of liver 
cancer. Intrahepatic organization of the liver lobule and the localization of hepatic cells that form 
liver tumors. Different types of cancer (i.e. HCC, iCCA, mixed HCC-iCCA) can originate in the 
liver depending on the transformation event and the cell type undergoing neoplastic 
transformation. Hepatic stem or progenitor cells are believed to reside within the most terminal 
branches of the biliary tree (referred to as Canals of Hering). Upon injury hepatocytes can 
undergo reversible ductal metaplasia and de-differentiate into hepatocyte-derived progenitor-like 
cells. 
 
Figure 3: Multiple cells of origin of primary liver cancers. HCC and iCCA can develop via 
transformation of mature hepatocytes and cholangiocytes, respectively. There is evidence that 
hepatic progenitor cells (HPCs), their intermediate states, or de-differentiated hepatocytes can 
form liver tumors with progenitor-like features, including mixed HCC-CCA, such as 
cholangiolocellular carcinoma (CLC). Mature hepatocytes can be also re-programmed into cells 
that closely resemble biliary epithelial cells and contribute to development of iCCA.  
 
Figure 4: Molecular biomarkers of HCC. Genetic features and gene expression of the tumor 
or its surrounding microenvironment correlate with clinical and pathology features, etiology, and 
patient outcomes. The proliferation subclass is characterized by proliferation signaling 
pathways, which involve proteins such as MTOR, Notch, and TGFB and several gene 
expression signatures associated with poor outcomes of patients (such as the G3 and 5-gene 
signatures)97. The non-proliferation subclass is characterized by mutations in CTNNB1, the S3 
gene expression signature, and the classical WNT signaling pathway. Specific mutations 
associated with etiology (smoking and aflatoxin B exposure) have also been described96. An 
expression pattern of 186 genes in the liver tissue surrounding the HCC can identify patients 
HCC at higher risk for tumor recurrence after resection103. 
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Figure 5: Main characteristics of subclasses of iCCA. Analyses of gene expression patterns 
have shown that iCCAs can be assigned to the proliferation or inflammation subclasses. The 
proliferation class is characterized by chromosome instability, activation of pathways related to 
cell cycle progression, mutations in oncogenes and shorter survival times of patients. Tumors of 
the inflammation subclass have gene expression patterns associated with activation of an 
immune response and less aggressive clinical behavior. FGFR2 fusion events are evenly 
distributed between these subclasses.  
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Notes: Author names in bold designate shared co-first authorship 
Table 1. Experimental models supporting the different hypotheses regarding the cell of origin in primary liver cancers                                                                                                       
Abbreviations: HPC, Hepatic progenitor cells; GEMM: genetically engineered mouse model; HCC, hepatocellular carcinoma; HPA, hepatocellular adenoma; iCCA, intrahepatic cholangiocarcinoma; 
mixed HCC-iCCA, mixed hepatocellular-cholangiocarcinoma; KO, knock-out; DKO, double knock-out; TKO, triple knock-out; DEN, N-nitrosodiethylamine; TAA, Thioacetamide; BDL, bile duct ligation; 
MDA, methylene dianiline; CDE, choline-deficient ethionine-supplemented; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine. 
 
 
Hypothesis tested Method Animal models 
Altered 
pathway Tumor Type Proposed cell of origin Reference 
HPC/oval cells as cell of 
origin  
Clonal analyses  - BMI1, WNT 
mixed HCC-
iCCA 
HPCs 51 
GEMM  Sav1fl/fl, mst1fl/fl, and mst2fl/fl  HIPPO HCC, iCCA oval cells  54 
GEMM  WW45flox/floxAlbumin-Cre HIPPO 
mixed HCC-
iCCA 
oval cells 55 
Multilineage 
differentiation  
- 
H-Ras, 
SV40LT 
HCC, iCCA 
HPC, hepatoblasts, 
hepatocytes 
57 
GEMM  Alb-Cre;Nf2lox/lox NF2 
HCC, iCCA, 
mixed 
oval cells 56 
GEMM  NotchIC::AlbCre NOTCH iCCA HPCs 62 
GEMM  Alb-Cre;LSL-IDH2R172K;LSL-KrasG12D IDH, KRAS iCCA hepatoblasts 63 
GEMM  LSL-KrasG12D -Ptenflox  KRAS, PTEN iCCA 
hepatoblasts, 
cholangiocytes 
64 
Hepatocytes as cell of 
origin 
GEMM AlfpCre+Trp53Δ2-10/Δ2-10  TP53, WNT HCC hepatocytes-derived HPC  52 
GEMM AlfpCre+Trp53Δ2-10/Δ2-10  
TP53, 
NOTCH 
iCCA hepatocytes-derived HPC  52 
GEMM  
(Mst1/Mst2 DKO, YAP KO, DKO Yap+/−, and 
tTKO 
HIPPO HCC 
hepatocytes-derived 
HPC/oval cells 
53 
Multilineage 
differentiation 
- 
H-Ras, 
SV40LT 
HCC, iCCA 
HPC, hepatoblasts, 
hepatocytes 
57 
lineage-tracing 
system  
liver injury (BDL, DDC, MDA, CDE); GEMM 
(Mdr2–/–) 
MDR HCC  hepatocytes 67 
lineage-tracing 
system  
liver injury (DEN); GEMM (Mdr2–/–;  PTEN-/-) MDR, PTEN HCC  hepatocytes 65 
lineage-tracing 
system   
DEN + TAA - HCC, HPA  hepatocytes 66 
GEMM  Tsc1/Sqstm1Δhep and Sqstm1Δhep/MUP  p62 HCC  hepatocytes 70 
lineage-tracing 
system   
Alb-CreERT2;R26RlacZ/+ and CK19-
CreERT2;R26RlacZ/+ 
NOTCH iCCA  hepatocytes 72 
lineage-tracing 
system 
hydrodinamic tail injection NOTCH, AKT iCCA 
 hepatocytes-derived 
biliary-like cells 
73 
        
 
    
Cholangiocytes as cell of 
origin 
 lineage-tracing 
system   
Liver injury (TAA) and CK19CreERTeYFPp53f/f TP53 iCCA cholangiocytes 26 
GEMM  LSL-KrasG12D -Ptenflox  KRAS, PTEN iCCA 
hepatoblasts, 
cholangiocytes 
64 
Table
Table 2. Prognostic signatures in primary liver cancer 
Signature Cohort (etiology) 
Number of patients 
tested 
Training/Validation set 
Clinical endpoint 
REMARK 
recommendations 
Level of evidence 
(Simon et al. JNCI 
2009) 
Reference 
Hepatocellular Carcinoma  
          
mRNA-based 
 
          
5-gene signature 
HCC (Alcohol, 
HCV, HBV) 
189/434 survival OK C 100 
EpCAM-signature HCC (HBV) 40/238 survival OK C 160 
186-gene signature (adjacent 
tissue) 
HCC (HCV) 82/441 
survival, HCC 
development 
OK C 103, 158 
miRNA based 
 
          
20-miRNA signature HCC (HBV) 131/110 
venous metastasis, 
survival 
OK C 161 
Down-regulation miR-26a HCC (HBV) 241/214 survival OK C 159 
DNA methylation 
 
          
36 CpG DNA methylation 
signature 
HCC (HCV) 221/83 survival OK C 102 
Protein markers (Plasma) 
 
          
Ang2, VEGF HCC (HCV) 491 survival OK B 157 
  
 
          
Cholangiocarcinoma  
          
mRNA-based 
 
          
poor prognosis/proliferation 
class 
iCCA 119/104 survival and recurrence further validation required C 85 
poor prognosis group iCCA and eCCA 52/52 survival and recurrence further validation required C 123 
Stem cell-like subtype 
iCCA and mixed 
HCC-CCA 
23/68 survival further validation required C 119 
              
Abbreviations: HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; mixed HCC-iCCA, mixed hepatocellular-cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma. 
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